Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038428 | 0.87 | GRM5 (0.55) | GRM5FFAR1HAO1 | |
| SCHEMBL2014187 | 0.85 | GRM5 (0.62) | GRM5FFAR1 | |
| SCHEMBL2008101 | 0.82 | GRM5 (0.65) | GRM5FFAR1 | |
| SCHEMBL2011460 | 0.78 | GRM5 (0.59) | GRM5FFAR1 | |
| SCHEMBL5042334 | 0.77 | GRM5 (0.57) | GRM5FFAR1HAO1 | |
| SCHEMBL5048046 | 0.77 | GRM5 (0.60) | GRM5FFAR1HAO1 | |
| SCHEMBL4630065 | 0.76 | GRM5 (0.51) | GRM5FFAR1 | |
| SCHEMBL5042306 | 0.76 | GRM5 (0.60) | GRM5FFAR1HAO1 | |
| SCHEMBL5038503 | 0.76 | GRM5 (0.57) | GRM5FFAR1 | |
| SCHEMBL5043844 | 0.76 | GRM5 (0.65) | GRM5FFAR1HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644351-B1 | Imidazole derivatives and their use in the treatment of mGluR5 receptor mediated disorders | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-7091222-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1644351-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005003117-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009878-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009878-A1 | Imidazole derivatives | GRIK5, GRM5, GRIK4 | GRM5 2/4885NPC1 634/4885RAB9A 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.